CB issuance terms amended, dilution 4.63%
차백신연구소
261780
Signal Score
Historical Avg Return (5d)
+0.72%
Data Coverage
100%n=2270
Risk-adjusted indicator based on 2270 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Dilution Ratio (Post-amendment): 4.63% of total shares
- • Dilution Ratio (Pre-amendment): 4.43% of total shares
3 more figures — Starter & Pro plans
AI Analysis Summary
CHA Vaccine Research Institute has filed an amendment to its convertible bond (CB) issuance, primarily modifying conversion and option terms. The potential dilution from the CB issuance has slightly increased from 4.43% to 4.63% of total shares. The company will pay 80 million KRW for the call option acquisition. Both put and call options offer an 8.0% annual compound yield. The amendment details adjustments to the conversion price, including a floor of 70% of the initial conversion price. This issuance could lead to moderate dilution for existing shareholders, although the specific use of funds is not detailed in this amendment.
Risk Factors
Pro plan
Access Full Korean Market Signal Analytics
✔ AI-parsed DART filing classification & scoring
✔ Real-time event impact indicators
✔ Price reaction & historical pattern data
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.